Ameritas Investment Partners
LCTX icon

Ameritas Investment Partners’s Lineage Cell Therapeutics LCTX Stock Holding History

Ameritas Investment Partners’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.9K Buy
+16,724
New +$23.1K ﹤0.01% 2709
2025
Q2 		– Sell
-10,656
Closed -$4.81K – 3273
2025
Q1 		$4.81K Hold
10,656
– – ﹤0.01% 2978
2024
Q4 		$5.36K Hold
10,656
– – ﹤0.01% 3017
2024
Q3 		$9.65K Hold
10,656
– – ﹤0.01% 2934
2024
Q2 		$10.6K Hold
10,656
– – ﹤0.01% 2900
2024
Q1 		$15.8K Hold
10,656
– – ﹤0.01% 2664
2023
Q4 		$11.6K Hold
10,656
– – ﹤0.01% 2799
2023
Q3 		$12.6K Hold
10,656
– – ﹤0.01% 2730
2023
Q2 		$15K Buy
+10,656
New +$14.7K ﹤0.01% 2713
2022
Q2 		– Sell
-9,508
Closed -$15K – 3159
2022
Q1 		$15K Hold
9,508
– – ﹤0.01% 2668
2021
Q4 		$23K Hold
9,508
– – ﹤0.01% 2576
2021
Q3 		$24K Hold
9,508
– – ﹤0.01% 2601
2021
Q2 		$27K Buy
+9,508
New +$24.6K ﹤0.01% 2568
2020
Q2 		– Sell
-6,005
Closed -$5K – 3100
2020
Q1 		$5K Hold
6,005
– – ﹤0.01% 2814
2019
Q4 		$5K Hold
6,005
– – ﹤0.01% 2901
2019
Q3 		$6K Hold
6,005
– – ﹤0.01% 2894
2019
Q2 		$7K Hold
6,005
– – ﹤0.01% 2886
2019
Q1 		$8K Hold
6,005
– – ﹤0.01% 2764
2018
Q4 		$5K Sell
6,005
-859
-13% -$1.32K ﹤0.01% 2858
2018
Q3 		$14K Hold
6,864
– – ﹤0.01% 2692
2018
Q2 		$12K Hold
6,864
– – ﹤0.01% 2780
2018
Q1 		$16K Hold
6,864
– – ﹤0.01% 2526
2017
Q4 		$13K Hold
6,864
– – ﹤0.01% 2658
2017
Q3 		$17K Hold
6,864
– – ﹤0.01% 2518
2017
Q2 		$19K Hold
6,864
– – ﹤0.01% 2487
2017
Q1 		$21K Buy
+6,864
New +$19.5K ﹤0.01% 2375

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Ameritas Investment Partners's LCTX Position: Q2 2026 in Review

Ameritas Investment Partners opened a new position in Lineage Cell Therapeutics (LCTX) in Q2 2026: 16,724 shares worth $21.9K. The stake represents ﹤0.01% of the portfolio and ranks #2709 among its holdings. This is a return to the name: Ameritas Investment Partners previously reported a position in LCTX as recently as Q1 2025.

Ameritas Investment Partners first reported a position in LCTX in Q1 2017 and has held it in 26 quarters since. The position peaked at $27K in Q2 2021. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Ameritas Investment Partners held 16,724 shares of Lineage Cell Therapeutics worth $21.9K as of Q2 2026.
  • Lineage Cell Therapeutics was a new Ameritas Investment Partners position in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #2709 holding.
  • Ameritas Investment Partners first reported a position in Lineage Cell Therapeutics in Q1 2017 and has held it in 26 quarters since.
  • Ameritas Investment Partners's Lineage Cell Therapeutics position peaked at $27K in Q2 2021.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.